|
| 37689822 | The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial. | Pharmacogenomics J | 2023 |
| 35134542 | CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. | J Mol Diagn | 2022 |
| 35342886 | Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. | Kidney360 | 2022 |
| 35660539 | Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. | Contemp Clin Trials | 2022 |
| 35452844 | Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing. | J Mol Diagn | 2022 |
| 35931342 | Characterization of Reference Materials for TPMT and NUDT15: A GeT-RM Collaborative Project. | J Mol Diagn | 2022 |
| 35177334 | Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). | Genet Med | 2022 |
| 35202484 | PharmVar GeneFocus: CYP3A5. | Clin Pharmacol Ther | 2022 |
| 35201852 | Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. | JCO Precis Oncol | 2022 |
| 32702149 | Tracheal Aspirate as an Alternative Biologic Sample for Pharmacogenomics Testing in Mechanically Ventilated Pediatric Patients. | Clin Transl Sci | 2021 |
| 33627827 | Expanding evidence leads to new pharmacogenomics payer coverage. | Genet Med | 2021 |
| 33622053 | Ending the pharmacogenomic gag rule: the imperative to report all results. | Pharmacogenomics | 2021 |
| 34020041 | Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project. | J Mol Diagn | 2021 |
| 34071920 | Multi-Institutional Implementation of Clinical Decision Support for <i>APOL1, NAT2,</i> and <i>YEATS4</i> Genotyping in Antihypertensive Management. | J Pers Med | 2021 |
| 34118403 | Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. | J Mol Diagn | 2021 |
| 34282303 | Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. | Genet Med | 2021 |
| 34109627 | PharmVar GeneFocus: CYP2C9. | Clin Pharmacol Ther | 2021 |
| 33288881 | Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. | Genet Med | 2021 |
| 33197628 | Characterization of Reference Materials for Spinal Muscular Atrophy Genetic Testing: A Genetic Testing Reference Materials Coordination Program Collaborative Project. | J Mol Diagn | 2021 |
| 32602114 | PharmVar GeneFocus: CYP2C19. | Clin Pharmacol Ther | 2021 |
| 32224869 | Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance. | Life (Basel) | 2020 |
| 31758698 | PharmVar and the Landscape of Pharmacogenetic Resources. | Clin Pharmacol Ther | 2020 |
| 31888882 | Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers. | Drug Metab Dispos | 2020 |
| 33232675 | BICRA, a SWI/SNF Complex Member, Is Associated with BAF-Disorder Related Phenotypes in Humans and Model Organisms. | Am J Hum Genet | 2020 |
| 32719393 | Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. | Genet Med | 2020 |
| 32869452 | EVEN-PLUS syndrome: A case report with novel variants in HSPA9 and evidence of HSPA9 gene dysfunction. | Am J Med Genet A | 2020 |
| 32923881 | Severe Capecitabine Toxicity Associated With a Rare <i>DPYD</i> Variant Identified Through Whole-Genome Sequencing. | JCO Precis Oncol | 2020 |
| 32980074 | Identifying End Users' Preferences about Structuring Pharmacogenetic Test Orders in an Electronic Health Record System. | J Mol Diagn | 2020 |
| 32380173 | Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists. | J Mol Diagn | 2020 |
| 30635623 | Response to Gammal et al. | Genet Med | 2019 |
| 30158693 | Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. | Genet Med | 2019 |
| 29997387 | Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. | Genet Med | 2019 |
| 29858578 | Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. | Genet Med | 2019 |
| 31401124 | Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project. | J Mol Diagn | 2019 |
| 31512387 | An unusual cause for Coffin-Lowry syndrome: Three brothers with a novel microduplication in RPS6KA3. | Am J Med Genet A | 2019 |
| 30794985 | Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology. | J Mol Diagn | 2019 |
| 30784356 | Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. | Pharmacogenomics | 2019 |
| 31075510 | Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. | J Mol Diagn | 2019 |
| 30489456 | Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. | Pharmacogenet Genomics | 2019 |
| 29102571 | Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. | JACC Cardiovasc Interv | 2018 |
| 29914287 | Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. | Pharmacogenomics | 2018 |
| 30351207 | Report of Confirmation of the rs7853758 and rs885004 Haplotype in SLC28A3. | Genet Test Mol Biomarkers | 2018 |
| 29474986 | Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. | J Mol Diagn | 2018 |
| 29483503 | Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. | Nat Commun | 2018 |
| 29280137 | Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. | Clin Pharmacol Ther | 2018 |
| 28532511 | Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. | BMC Med Genomics | 2017 |
| 28294551 | The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. | Clin Transl Sci | 2017 |
| 28212969 | Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice. | Value Health | 2017 |
| 26850569 | Implementation of a pharmacogenomics consult service to support the INGENIOUS trial. | Clin Pharmacol Ther | 2016 |
| 26621101 | Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. | J Mol Diagn | 2016 |